Psychological status of elderly patients suffering arterial hypertension in metabolic syndrome against the background of chronotherapy

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Arterial hypertension in the metabolic syndrome in the elderly contributes to the formation of cognitive disorders and anxiety-depressive disorders. It is shown that the severity of these deviations of the psychological continuum significantly decreases after 1 year, under the influence of an antihypertensive fixed combination of amlodipine, mesinopril and rosuvastatin in the chronotherapy mode (evening reception), than in the traditional application (morning reception in the equivalent dosage of 5/10/10 mg per day in both cases. The dynamics of cognitive impairment in chronotherapeutical approach in patients 60–74 flights from arterial hypertension with metabolic syndrome is characterized by a significant increase in the average score on a scale MMSE, f source 17.8 ± 0.3 to 23.5 ± 0.4 points (р < 0.001), against 16.9 ± 0.3 to 20.4 ± 0.4 points (р < 0.001) in the morning taking the drug. Situational anxiety decreased from 40.8 ± 2.2 to 30.6 ± 1.8 points (р > 0.05) and from 40.0 ± 2.5 to 32.1 ± 2.0 points (р > 0.05), personal anxiety from 48.8 ± 2.0 to 25.4 ± 1.9 (р < 0.001) and from 44.9 ± 1.9 to 30.7 ± 1.7 (р < 0.01) points in the evening and morning the reception, respectively. Depressive disorders decreased slightly more significantly in chronotherapy (14.1% vs. 7.7%) than in the traditional scheme, but despite this, both cases with (groups) corresponded to depressive spectrum disorders. The results obtained indicate that chronotherapy is more effective than the traditional use of a fixed combination of amlodipine, lisinopril and rosuvastatin in arterial hypertension with metabolic syndrome.

Full Text

Restricted Access

About the authors

Nikolai M. Agarkov

Southwestern State University; Belgorod State National Research University

Author for correspondence.
Email: vitalaxen@mail.ru

doctor of medical sciences, professor of the department of biomedical engineering, Southwestern State Donation University

Russian Federation, Kursk; Belgorod

Oleg I. Okhotnikov

Kursk State Medical University

Email: vitalaxen@mail.ru

doctor of medical sciences, professor

Russian Federation, Kursk

Snezhana I. Korneeva

Kursk State Medical University

Email: mitikhina2@mail.ru

candidate of medical sciences

Russian Federation, Kursk

Ekaterina O. Moskaleva

Belgorod State National Research University

Email: vitalaxen@mail.ru

student

Russian Federation, Belgorod

Alexander A. Moskalev

Belgorod State National Research University

Email: anton-titov-2001@mail.ru

student

Russian Federation, Belgorod

Vsevolod I. Kolomyets

Kursk State Medical University

Email: kurskmed@mail.ru

resident

Russian Federation, Kursk

Alexandra M. Markelova

Information and Methodological Center for Examination, Accounting and Analysis of Means of Medical Use

Email: markela@yandex.ru

an employee

Russian Federation, Kursk

References

  1. Sergeeva VA. Principles of antihypertensive therapy in metabolic syndrome. Klinicheskaya medicina. 2013;91(6):4–8. (In Russ.).
  2. Zhang J, Liu N, Yang Ch. Effects of rosuvastatin in comdination with nimodipine in patients with mild cognitive impairment caused by cerebral small vessel disease. Panminerra Med. 2019;61(4):439–443. doi: 10.23736/S0031-0808.18.03475-4
  3. Toshima T. Risk factors for the metabolic syndrome components of hypertension, diabetes mellitus, and dyslipidemia after living donor liver transplantation. HPB (Oxford). 2019;1365(182):30695–30701. doi: 10.1016/j.hpb.2019.08.008
  4. Satybaldieva AD. Features of the course of essential arterial hypertension in the elderly and senile age. Vestnik Almatinskogo gosudarstvennogo instituta usovershenstvovaniya vrachej. 2017;1:22–28. (In Russ.).
  5. Kryukov EV, Potekhin NP, Fursov AN, et al. Hypertensive crisis: modern view of the problem and optimization of diagnostic and therapeutic modalities. Clinical Medicine (Russian Journal). 2016;94(1):52–56. (In Russ.).
  6. Zhang J, Wang WL. Risk factors of metabolic syndrome after liver transplantation. Hepatobiliary Pancreat Dis Int. 2015;14(6):582–587. doi: 10.1016/S1499-3872(15)60037-6
  7. Ascaso JF. Prevalence of metabolic syndrome and cardiovascular disease in a hypertriglyceridemic population. Eur J Intern Med. 2011;22(2):177–181. doi: 10.1016/j.ejim.2010.12.011
  8. Gasparyan AYu. Features of metabolic syndrome in elderly and senile people, residents of besieged Leningrad. Sistemnye gipertenzii. 2008;5;263–269. (In Russ.).
  9. Dzherieva IS. Association between depression and metabolic syndrome. Klinicheskaya medicina. 2015;93(1):62–65. (In Russ.).
  10. Mikhailovskaya NS. Relationship of anxiety and depressive disorders with the course of coronary heart disease, comorbid with metabolic syndrome. Zaporozhskij medicinskij zhurnal. 2015;5:23–27. (In Russ.).
  11. Ostroumova OD. Effect of drugs with anticholinergic activity on the cognitive functions of patients 80 years and older with essential arterial hypertension. Arterial'naya gipertenziya. 2019;25(3):246–257. (In Russ.).
  12. Ibrahim MS. Risk models and scores for metabolic syndrome: systematic review protocol. BMJ OPEN. 2019;9(9):e027326. doi: 10.1136/bmjopen-2018-027326
  13. Rekomendacii ekspertov Vserossijskogo nauchnogo obshchestva kardiologov po diagnostike i lecheniyu metabolicheskogo sindroma (vtoroj peresmotr). Prakticheskaya medicina. 2010;44(5):81–101. (In Russ.).
  14. Nacional'nye rekomendacii ekspertov Vserossijskogo nauchnogo obshchestva kardiologov po diagnostike i lecheniyu arterial'noj gipertenzii (4-j peresmotr). Sistemnye gipertenzii. 2010;3:5–26. (In Russ.).
  15. Folstein MF, Folstein SE, McHugh PR. «Mini-mental state». A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research. 1975;12(3):189–198. doi: 10.1016/0022-3956(75)90026-6
  16. Khanin YuL. Research on anxiety in sports. Voprosy psihologii. 1978;6:92–99. (In Russ.).
  17. Andryushchenko AV, Drobizhev MYu, Dobrovolsky AV. Comparative evaluation of the CES–D, BDI and HADS(D) scale in the diagnosis of depression in General medical practice. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2003;5:11–18. (In Russ.).
  18. World Medical Association. Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–2194. doi: 10.1001/jama.2013.281053

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Dynamics of cognitive impairment by mean MMSE scale score at evening amlodipine, lisinopril and rosuvastatin (a) and morning (b) amlodipine fixed combination intake in elderly patients suffering from artherial hyperstention in metabolic syndrome (M ± m)

Download (84KB)
Indexing metadata
3. Fig. 2. Dynamics of situational anxiety during evening intake of fixed combination amlodipine, lisinopril and rosuvastatin (a) and morning (b) in elderly patients suffering from artherial hyperstention in metabolic syndrome (M ± m)

Download (96KB)
Indexing metadata
4. Fig. 3. Dynamics of personal anxiety during evening (a) and morning (b) intake of fixed combination amlodipine, lisinopril and rosuvastatin in elderly patients suffering from metabolic syndrome with artherial hyperstention (M ± m)

Download (89KB)
Indexing metadata
5. Fig. 4. Dynamics of depressive disorders on the CES-D scale during evening (a) and morning (b) intake of fixed combination amlodipine, lisinopril and rosuvastatin in elderly patients suffering from artherial hyperstention in metabolic syndrome (M ± m)

Download (97KB)
Indexing metadata

Copyright (c) 2021 Agarkov N.M., Okhotnikov O.I., Korneeva S.I., Moskaleva E.O., Moskalev A.A., Kolomyets V.I., Markelova A.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 77762 от 10.02.2020.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies